A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic <i>BRAF</i> -Mutated Thyroid Cancer in Japan
Makoto Tahara, Naomi Kiyota, Hiroo Imai, Shunji Takahashi, Akihiro Nishiyama, Shingo Tamura, Yasushi Shimizu, Shigenori Kadowaki, Ken‐ichi Ito, Masahiro Toyoshima, Yoshinori Hirashima, Shinji Ueno, Iwao Sugitani
Abstract
Background: Driver mutations at BRAF V600 are frequently identified in papillary thyroid cancer and anaplastic thyroid cancer (ATC), in which BRAF inhibitors have shown clinical effectiveness. This Japanese phase 2 study evaluated the efficacy and safety of a BRAF inhibitor, encorafenib, combined with an MEK inhibitor, binimetinib, in patients with BRAF V600-mutated thyroid cancer.
Topics & Concepts
MedicineAnaplastic thyroid cancerThyroid cancerInternal medicineOncologyClinical endpointCancerPapillary thyroid cancerPhases of clinical researchRegimenPopulationThyroidChemotherapyClinical trialEnvironmental healthThyroid Cancer Diagnosis and TreatmentCancer-related Molecular Pathways